Viatris people and HR interviews test whether candidates understand how managing talent at a complex generics and off-patent pharmaceutical company differs from branded pharma or technology HR – where the November 2020 Mylan-Upjohn combination brought together two distinct corporate cultures requiring organizational integration that blended Mylan's entrepreneurial generic pharmaceutical identity with Pfizer Upjohn's established big-pharma operating model, governance standards, and compensation structures in ways that created retention risk for key employees uncertain about their place in the combined organization, where commercial compliance training requirements under the Anti-Kickback Statute and state pharmaceutical marketing disclosure laws create HR obligations to maintain trained, compliant sales forces whose interactions with healthcare providers are governed by rules that do not apply in other industries, and where the November 2022 divestiture of Viatris's biosimilar business to Biocon Biologics required HR to manage the transfer of employees in the biosimilar commercial and development functions to Biocon while maintaining the morale and engagement of remaining Viatris employees who were not part of the divestiture. HR at Viatris spans post-combination integration and workforce alignment (where integrating the Mylan and Upjohn workforces required decisions about organizational structure, role consolidation, compensation harmonization across two different pay structures, and benefit plan integration that affected thousands of employees globally while the combined company established the Viatris culture and operating model as distinct from both predecessor companies), pharmaceutical commercial compliance training and HCP interaction governance (where the Anti-Kickback Statute's prohibition on remuneration offered in exchange for healthcare provider referrals applies to Viatris's sales force interactions, speaker bureau honoraria, and advisory board engagements, requiring HR to design and maintain training programs that establish and reinforce the compliance boundaries for commercial employees who interact with prescribers and healthcare institutions), scientific and regulatory talent acquisition and retention (where regulatory affairs specialists, pharmacokinetics scientists, analytical chemists, and patent attorneys who understand generic pharmaceutical development create a specialized talent market where pharmaceutical industry experience is required and where Viatris competes against generic companies like Teva and Sun Pharmaceutical and research-based companies recruiting from the same talent pool), and global HR management across 165 countries (where Viatris's international operations require country-level employment law compliance, local compensation market benchmarking, and works council or union relations management in European countries where employee representation has legal standing in organizational decisions).

Start your free Viatris People & HR practice session.

What interviewers actually evaluate

Post-Combination Integration, Commercial Compliance Training, and Scientific Talent Management

Viatris HR interviews probe whether candidates understand how managing talent at a combined pharmaceutical company differs from standalone pharma HR in the integration culture challenge (Mylan N.V. built its identity as an independent generic pharmaceutical company known for aggressive patent challenges, lower-cost manufacturing, and a competitive commercial culture, while Pfizer Upjohn represented the legacy of one of the world's largest research-based pharmaceutical companies with structured governance, established compliance programs, and premium compensation – and the HR integration task of creating a unified Viatris identity required preserving the commercial agility and cost discipline of the Mylan culture while adopting the compliance infrastructure and governance standards of Pfizer without the organizational complexity that made Pfizer's model unsuitable for a generic-focused business), the pharmaceutical commercial compliance training imperative (the Anti-Kickback Statute's broad prohibition on offering, paying, soliciting, or receiving remuneration to induce or reward healthcare provider referrals creates compliance risk in every interaction between Viatris's commercial employees and prescribers – where a sales representative who provides a meal, speaking honorarium, or advisory board payment to a physician must be trained to understand which commercial interactions are protected under the AKS safe harbors and which create liability, and where HR must maintain training documentation that demonstrates compliance program implementation as required by the OIG's Corporate Integrity Agreement framework that pharmaceutical companies frequently operate under following settlement of government investigations), and the global HR complexity across 165 countries (managing employment relationships in markets ranging from the United States and Germany to India, China, and dozens of emerging market countries requires HR professionals who understand the legal and cultural differences in employer obligations, union and works council rights, termination procedures, and compensation benchmarking across markets where Viatris's cost structure requires competitive but not premium talent management).

The biosimilar business divestiture to Biocon Biologics created an HR challenge that standard acquisitions do not generate in reverse: transferring employees to a new employer requires careful management of the legal requirements for transfer of employment contracts in each country, communication to transferring employees about their new employment terms and any changes in benefits or compensation that the Biocon employment relationship creates, and retention of the remaining Viatris employees who may have had colleague relationships with the transferred employees and who are watching how Viatris treats employees who are part of a transaction.

What gets scored in every session

Specific, sentence-level feedback.

Dimension What it measures How to answer
Post-combination culture integration and organizational design Do you understand how to develop the Viatris culture integration strategy following the Mylan-Upjohn combination – how to assess which elements of each predecessor company's culture create value in the combined organization versus which represent incompatible operating assumptions that must be resolved through a designed Viatris culture rather than organic cultural drift, what the organizational design decisions are about centralized versus decentralized decision-making that reflect the combined company's strategy for a generic pharmaceutical business with global manufacturing and commercial operations, and how to manage retention of key employees who joined from either Mylan or Upjohn and who are evaluating whether the combined Viatris organization offers a career environment that matches what attracted them to their predecessor company? We flag HR answers that describe post-merger integration as communication and training programs without engaging with the organizational design decisions and cultural value assessment that determine whether the combined company develops a coherent identity or remains two cultures in the same legal entity. Culture assessment and design framework, organizational centralization decisions, key employee retention investment
Pharmaceutical commercial compliance training and AKS safe harbor management Can you describe how to develop Viatris's commercial compliance training program for sales representatives and medical science liaisons who interact with healthcare providers – what the Anti-Kickback Statute's safe harbor provisions are for pharmaceutical company interactions including the nominal value exception for promotional items, the legitimate services fair market value requirement for speaker bureau arrangements, and the bona fide service requirement for advisory board engagements, how to structure the annual compliance training that ensures commercial employees understand which interactions are permitted versus which create legal risk, and how to manage the situation when a sales representative's expense report shows a pattern of HCP meals that individually appear to be within policy but collectively suggest a compensatory relationship that may not qualify for the nominal value safe harbor? We score whether your commercial compliance training engages with the specific AKS safe harbor structure and the pattern recognition that distinguishes legitimate commercial interactions from remuneration arrangements that create liability. AKS safe harbor application to commercial interactions, annual training content and documentation, pattern-of-conduct compliance investigation
Scientific and regulatory talent acquisition for generic pharmaceutical development Do you understand how to recruit and retain the regulatory affairs, pharmacokinetics, and analytical chemistry talent that Viatris's ANDA development pipeline requires – what the employer value proposition elements are that differentiate a Viatris regulatory affairs career from comparable roles at Teva, Sun Pharmaceutical, or the regulatory consulting firms that employ the same talent pool, how to assess whether a regulatory affairs candidate's ANDA experience is in technically comparable product categories to Viatris's complex generic development priorities, and how to design the development path for regulatory affairs scientists that provides sufficient specialization depth to make them valuable ANDA writers while also developing the project management and cross-functional coordination skills that senior regulatory positions require? We detect HR answers that treat pharmaceutical scientific talent acquisition as standard technical recruitment without engaging with the ANDA experience assessment and career development pathway that distinguish genuinely qualified regulatory science candidates from candidates with general pharmaceutical regulatory backgrounds. ANDA experience assessment criteria, regulatory science career development pathway, competitive differentiation from generic pharma peers
Global HR management and European works council relations Can you describe how to manage Viatris's HR function across 165 countries – how to develop the global HR operating model that provides consistent policy frameworks and talent development infrastructure while delegating country-level employment law compliance and local market adaptation to regional HR teams, what the works council consultation obligations are for decisions affecting Viatris's German or Dutch operations including restructuring decisions that eliminate positions or change reporting structures, and how to manage the global compensation philosophy that maintains competitive positioning in each market without creating internal equity concerns when salary ranges in different countries reflect purchasing power differences that employees in different locations may perceive as unfair? We flag HR answers that describe global HR as consistent policy application across all countries without engaging with the European works council consultation requirements and local employment law differences that require genuine local adaptation rather than global policy enforcement. Global HR operating model with local adaptation, European works council consultation scope, global compensation philosophy design

How a session works

Step 1: Choose a Viatris HR scenario – post-combination culture integration and organizational design, pharmaceutical commercial compliance training and Anti-Kickback Statute management, scientific and regulatory talent acquisition for ANDA development, or global HR management across 165 countries.

Step 2: The AI interviewer asks realistic Viatris-style questions: how you would design the organizational integration plan for Viatris's global regulatory affairs function – which was previously split between Mylan's regulatory team focused on ANDA submissions and paragraph IV challenges and Upjohn's regulatory team with international market registration expertise – including how to assess which capabilities should be centralized in a global regulatory center of excellence versus maintained in regional teams close to the markets they serve, what the transition plan is for consolidating duplicate regulatory project management functions without losing the institutional knowledge that experienced regulatory affairs specialists hold about specific product dossiers that are in active FDA review, and how to design the performance management framework for the combined regulatory team that recognizes both ANDA submission quality and international registration maintenance contributions; how you would respond when Viatris's corporate compliance team escalates a report from the internal hotline alleging that a regional sales manager in the Southeast has been taking a group of prescribers to premium sporting events multiple times per year at a cost that exceeds what the speaker bureau honorarium records show as fair market value payments – including what the initial fact-finding investigation involves, how to assess whether the reported conduct creates AKS liability versus falls within Viatris's compliance policy, and how to manage the employee relations aspects of the investigation when the sales manager has been a high performer with strong district-level relationships; or how you would develop Viatris's strategy for retaining 25 key regulatory affairs scientists at the West Virginia ANDA development center who were notified that their facility will transition to a third-party contract research organization model within 18 months – including what the retention bonus structure looks like for scientists needed through the full transition period, how to communicate transition timelines and outplacement support in a way that maintains productivity during the transition without triggering immediate departures, and what the competitive offer assessment is for Viatris scientists who receive outside offers from Teva or Perrigo during the transition period.

Step 3: You respond as you would in the actual interview. The system scores your answer on post-combination integration, commercial compliance training, scientific talent management, and global HR operations.

Step 4: You get sentence-level feedback on what demonstrated genuine pharmaceutical HR expertise and what needs stronger AKS compliance program specificity or scientific talent acquisition analysis.

Frequently Asked Questions

How did the Mylan-Upjohn combination create HR integration challenges?
The November 2020 combination brought together Mylan N.V.'s approximately 35,000 employees with Pfizer Upjohn's global workforce across more than 60 countries, requiring HR to design a combined Viatris organization that integrated these workforces with different compensation structures, benefit plans, performance management frameworks, and cultural expectations. Mylan employees had built careers at an aggressive generic pharmaceutical company where financial performance and competitive positioning drove advancement, while Upjohn employees came from Pfizer's highly structured environment with premium compensation, extensive benefits, and compliance-driven operating procedures. The HR integration required decisions about which Pfizer compensation and benefit standards could be maintained in the combined company versus which needed to be adjusted to reflect Viatris's different cost structure as a generic pharmaceutical business, alongside organizational decisions about which functions would be centralized under the Viatris corporate structure versus maintained in regional or business unit-level roles.

What is the Anti-Kickback Statute and how does it affect Viatris's commercial workforce?
The federal Anti-Kickback Statute prohibits offering, paying, soliciting, or receiving remuneration in exchange for referrals of items or services covered by federal healthcare programs including Medicare and Medicaid. For Viatris's commercial workforce, the AKS applies to interactions with prescribers and healthcare institutions because prescribers' decisions to write prescriptions for Viatris products may constitute referrals covered by the statute. Common pharmaceutical commercial activities that require AKS analysis include speaker bureau honoraria for physician speakers at promotional programs, advisory board payments to physician advisors, meals provided during sales detail calls, and medical education grants – each of which can qualify for AKS safe harbor protection if structured to meet the safe harbor's requirements for legitimate services, fair market value compensation, and non-inducement intent. HR's role is ensuring that commercial employees are trained to understand the safe harbor requirements and that the compliance program maintains documentation demonstrating that all HCP interactions met the applicable safe harbor requirements.

What scientific talent is most critical for Viatris's ANDA development pipeline?
Viatris's complex generic development pipeline requires scientists with specialized expertise in areas that general pharmaceutical industry training does not fully develop. Regulatory affairs scientists with specific ANDA filing experience – including knowledge of bioequivalence study design, chemistry manufacturing and controls submission requirements, and paragraph IV certification strategy – are particularly valuable because ANDA regulatory submissions require deep familiarity with FDA's generic drug guidance documents and review standards that differ significantly from NDA regulatory strategy. Pharmacokinetics scientists who specialize in bioequivalence study design and data analysis for complex drug formulations including extended-release, transdermal, and inhalation products are in demand because complex generic bioequivalence often requires clinical studies rather than simple in vitro dissolution testing. Analytical chemists with expertise in pharmaceutical impurity characterization, stability testing, and specification setting for complex molecules are critical for the chemistry, manufacturing, and controls sections of ANDA submissions.

How does Viatris manage commercial compliance under a Corporate Integrity Agreement?
Pharmaceutical companies that resolve government investigations of Anti-Kickback Statute violations or False Claims Act allegations often enter Corporate Integrity Agreements with the Office of Inspector General that require implementation of enhanced compliance programs including independent review organization audits, annual compliance certifications, and compliance training documentation maintained for OIG review. If Viatris or its predecessor companies operated under CIA obligations, HR's commercial compliance training function must maintain the training documentation, attendance records, and competency assessment results that CIA reporting requirements specify. Even absent a CIA, pharmaceutical industry best practices recommend structured commercial compliance training programs that document that all commercial employees received training on AKS requirements, company policy boundaries for HCP interactions, and reporting procedures for potential compliance concerns – creating an HR compliance documentation obligation that does not exist in non-healthcare industries.

How does Viatris manage HR across 165 countries with different employment laws?
Viatris's HR function uses a tiered operating model where global HR policies establish consistent frameworks for talent management, compensation philosophy, and compliance standards across all countries, while regional HR teams adapt implementation to comply with local employment laws, negotiated collective agreements, and cultural expectations in each market. European operations require particular adaptation because the EU's Working Time Directive, equal treatment requirements, and national-level codetermination laws create employer obligations that do not exist in Viatris's US market. German operations, for example, require works council consultation before implementing certain organizational changes, and French operations require information and consultation with the Comite Social et Economique for significant business decisions affecting employees. India operations, where Viatris has significant manufacturing workforce, require compliance with India's extensive labor law framework including the Factories Act, Industrial Disputes Act, and state-level shops and establishments legislation.

Also practice

One full session free. No account required. Real, specific feedback.